LATEST ARTICLES
The Israeli Patent Office issued a significant ruling on Patent Application No. 204013, partially revoking Amgen’s broad claims covering PCSK9-targeting antibodies used to lower LDL...
The Israeli Supreme Court recently issued a decision on a patent term extension (PTE) for Patent No. 148756, which covers Nintedanib, a drug developed by Boehringer Ingelheim. The case...
A recent ruling by the Israeli Patent Office revoked the patent term extension (PTE) for Patent No. 160693, covering the anticoagulant drug Eliquis (Apixaban). The decision followed...
In 2008, Teva challenged the patent application for the dehydrophosphate salt (DHP) of sitagliptin. The primary reference was the “basic patent” of sitagliptin, which detailed and claimed...
In the 1980s, Sanofi developed Plavix, a medication aimed at preventing strokes. The basic patent, which protected both the molecule and its Form 1 polymorph, expired in 2008, theoretically...
A patent application for Lumateperone tosylate, a compound used in schizophrenia treatment, was recently rejected by both an examiner and the patent registrar. The grounds for refusal?...